Multiparametric In-vitro Cardiotoxicity Testing refers to a set of laboratory-based techniques and assays used to evaluate the potential toxic effects of drugs, chemicals, or other substances on the cardiovascular system. It involves the assessment of multiple parameters or endpoints to comprehensively evaluate the cardiac safety profile of a substance.
The global Multiparametric In-vitro Cardiotoxicity Testing market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
As the demands of drug development and chemical evaluation increase, the need for cardiotoxicity testing is also growing. Traditional animal testing methods have limitations such as high cost, long time, and ethical and moral issues, while Multiparametric in-vitro cardiotoxicity testing provides an alternative. By using cardiac cells, tissues or models, combined with multi-parameter measurements, it can more accurately evaluate the toxic effects of compounds on the heart, thereby improving the efficiency of drug safety assessment and chemical screening.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Multiparametric In-vitro Cardiotoxicity Testing market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Hemogenix
Molecular Devices
Creative Bioarray
FUJIFILM Cellular Dynamics
Agilent Technologies
Merck KGaA
Axol Bioscience
Miltenyi Biotec
Evotec
Enzo Life Sciences
Stemina Biomarker Discovery
Eurofins Discovery
Segment by Type
Calcium Transient Assay
Cardiac Marker Detection
Multi-ion Channel Assay
Others
Segment by Application
Contract Research Organizations (CROs)
Pharmaceutical and Biotech Companies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Multiparametric In-vitro Cardiotoxicity Testing report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Calcium Transient Assay
1.2.3 Cardiac Marker Detection
1.2.4 Multi-ion Channel Assay
1.2.5 Others
1.3 Market by Application
1.3.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Contract Research Organizations (CROs)
1.3.3 Pharmaceutical and Biotech Companies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Perspective (2018-2029)
2.2 Multiparametric In-vitro Cardiotoxicity Testing Growth Trends by Region
2.2.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Multiparametric In-vitro Cardiotoxicity Testing Historic Market Size by Region (2018-2023)
2.2.3 Multiparametric In-vitro Cardiotoxicity Testing Forecasted Market Size by Region (2024-2029)
2.3 Multiparametric In-vitro Cardiotoxicity Testing Market Dynamics
2.3.1 Multiparametric In-vitro Cardiotoxicity Testing Industry Trends
2.3.2 Multiparametric In-vitro Cardiotoxicity Testing Market Drivers
2.3.3 Multiparametric In-vitro Cardiotoxicity Testing Market Challenges
2.3.4 Multiparametric In-vitro Cardiotoxicity Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Multiparametric In-vitro Cardiotoxicity Testing Players by Revenue
3.1.1 Global Top Multiparametric In-vitro Cardiotoxicity Testing Players by Revenue (2018-2023)
3.1.2 Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share by Players (2018-2023)
3.2 Global Multiparametric In-vitro Cardiotoxicity Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Multiparametric In-vitro Cardiotoxicity Testing Revenue
3.4 Global Multiparametric In-vitro Cardiotoxicity Testing Market Concentration Ratio
3.4.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Multiparametric In-vitro Cardiotoxicity Testing Revenue in 2022
3.5 Multiparametric In-vitro Cardiotoxicity Testing Key Players Head office and Area Served
3.6 Key Players Multiparametric In-vitro Cardiotoxicity Testing Product Solution and Service
3.7 Date of Enter into Multiparametric In-vitro Cardiotoxicity Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Multiparametric In-vitro Cardiotoxicity Testing Breakdown Data by Type
4.1 Global Multiparametric In-vitro Cardiotoxicity Testing Historic Market Size by Type (2018-2023)
4.2 Global Multiparametric In-vitro Cardiotoxicity Testing Forecasted Market Size by Type (2024-2029)
5 Multiparametric In-vitro Cardiotoxicity Testing Breakdown Data by Application
5.1 Global Multiparametric In-vitro Cardiotoxicity Testing Historic Market Size by Application (2018-2023)
5.2 Global Multiparametric In-vitro Cardiotoxicity Testing Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Multiparametric In-vitro Cardiotoxicity Testing Market Size (2018-2029)
6.2 North America Multiparametric In-vitro Cardiotoxicity Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2018-2023)
6.4 North America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size (2018-2029)
7.2 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2018-2023)
7.4 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size (2018-2029)
8.2 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region (2018-2023)
8.4 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Size (2018-2029)
9.2 Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2018-2023)
9.4 Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size (2018-2029)
10.2 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2018-2023)
10.4 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Hemogenix
11.1.1 Hemogenix Company Detail
11.1.2 Hemogenix Business Overview
11.1.3 Hemogenix Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.1.4 Hemogenix Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.1.5 Hemogenix Recent Development
11.2 Molecular Devices
11.2.1 Molecular Devices Company Detail
11.2.2 Molecular Devices Business Overview
11.2.3 Molecular Devices Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.2.4 Molecular Devices Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.2.5 Molecular Devices Recent Development
11.3 Creative Bioarray
11.3.1 Creative Bioarray Company Detail
11.3.2 Creative Bioarray Business Overview
11.3.3 Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.3.4 Creative Bioarray Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.3.5 Creative Bioarray Recent Development
11.4 FUJIFILM Cellular Dynamics
11.4.1 FUJIFILM Cellular Dynamics Company Detail
11.4.2 FUJIFILM Cellular Dynamics Business Overview
11.4.3 FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.4.4 FUJIFILM Cellular Dynamics Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.4.5 FUJIFILM Cellular Dynamics Recent Development
11.5 Agilent Technologies
11.5.1 Agilent Technologies Company Detail
11.5.2 Agilent Technologies Business Overview
11.5.3 Agilent Technologies Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.5.4 Agilent Technologies Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.5.5 Agilent Technologies Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Detail
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.6.4 Merck KGaA Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.6.5 Merck KGaA Recent Development
11.7 Axol Bioscience
11.7.1 Axol Bioscience Company Detail
11.7.2 Axol Bioscience Business Overview
11.7.3 Axol Bioscience Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.7.4 Axol Bioscience Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.7.5 Axol Bioscience Recent Development
11.8 Miltenyi Biotec
11.8.1 Miltenyi Biotec Company Detail
11.8.2 Miltenyi Biotec Business Overview
11.8.3 Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.8.4 Miltenyi Biotec Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.8.5 Miltenyi Biotec Recent Development
11.9 Evotec
11.9.1 Evotec Company Detail
11.9.2 Evotec Business Overview
11.9.3 Evotec Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.9.4 Evotec Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.9.5 Evotec Recent Development
11.10 Enzo Life Sciences
11.10.1 Enzo Life Sciences Company Detail
11.10.2 Enzo Life Sciences Business Overview
11.10.3 Enzo Life Sciences Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.10.4 Enzo Life Sciences Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.10.5 Enzo Life Sciences Recent Development
11.11 Stemina Biomarker Discovery
11.11.1 Stemina Biomarker Discovery Company Detail
11.11.2 Stemina Biomarker Discovery Business Overview
11.11.3 Stemina Biomarker Discovery Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.11.4 Stemina Biomarker Discovery Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.11.5 Stemina Biomarker Discovery Recent Development
11.12 Eurofins Discovery
11.12.1 Eurofins Discovery Company Detail
11.12.2 Eurofins Discovery Business Overview
11.12.3 Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.12.4 Eurofins Discovery Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2018-2023)
11.12.5 Eurofins Discovery Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Hemogenix
Molecular Devices
Creative Bioarray
FUJIFILM Cellular Dynamics
Agilent Technologies
Merck KGaA
Axol Bioscience
Miltenyi Biotec
Evotec
Enzo Life Sciences
Stemina Biomarker Discovery
Eurofins Discovery
Ěý
Ěý
*If Applicable.
